13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595855
Total reported value
$1.1B
$1.1B
54 檔
35.3%
As reported in its official Q4 2025 Form 13F filing, Opaleye Management Inc.'s tracked investment portfolio stood at $1.1B with 54 total positions.
In Q4 2025, Opaleye Management Inc. displayed an active expansion posture, initiating 21 new positions and adding to 16 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | Stock-Other | 25.25% | -3.92% | — | |
| 2 | LQDA | Liquidia CORP | Stock-Other | 11.21% | +5.97% | -6.88% | |
| 3 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 6.38% | +0.08% | — | |
| 4 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.66% | -3.42% | -28.52% | |
| 5 | APGE | Apogee Therapeutics Inc | Stock-Other | 3.87% | +0.37% | +6.88% | |
| 6 | SNWV | Sanuwave Health Inc | Stock-Other | 3.86% | -1.95% | +0.13% | |
| 7 | STOK | Stoke Therapeutics Inc | Stock-Other | 2.91% | -0.93% | +1.90% | |
| 8 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.55% | -0.14% | — | |
| 9 | ✓ | Stock-Other | 2.52% | -1.86% | +121.51% | ||
| 10 | CGON | Cg Oncology Inc | Stock-Other | 2.25% | -0.74% | — | |
| 11 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 2.10% | +0.32% | — | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 2.10% | +2.11% | +3.21% | |
| 13 | RZLT | Rezolute Inc | Stock-Other | 1.96% | +0.44% | +595.91% | |
| 14 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.84% | -1.03% | — | |
| 15 | ALKS | Alkermes plc | Stock-Healthcare | 1.81% | — | +8.89% | |
| 16 | ACOG | Alpha Cognition Inc | Stock-Other | 1.78% | +0.04% | +1698.46% | |
| 17 | ANNX | Annexon Inc | Stock-Other | 1.72% | -0.81% | — | |
| 18 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.64% | -0.23% | — | |
| 19 | CDXS | Codexis Inc | Stock-Other | 1.46% | -0.07% | -46.93% | |
| 20 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.21% | -0.28% | — | |
| 21 | GOSS | Gossamer Bio Inc | Stock-Other | 1.11% | — | -0.18% | |
| 22 | MBX | Mbx Biosciences Inc | Stock-Other | 1.08% | +0.28% | +2.77% | |
| 23 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.05% | +0.42% | — | |
| 24 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.03% | +0.06% | +14.70% | |
| 25 | DERM | Journey Medical CORP | Stock-Other | 0.99% | -0.37% | +0.41% | |
| 26 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.90% | — | — | |
| 27 | JBIO | Jade Biosciences Inc | Stock-Other | 0.87% | -0.50% | — | |
| 28 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.83% | +1.41% | — | |
| 29 | ALMS | Alumis Inc | Stock-Other | 0.69% | -0.20% | -19.55% | |
| 30 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.66% | -2.57% | EXIT | |
| 31 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.62% | -0.20% | — | |
| 32 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.60% | -0.27% | — | |
| 33 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.59% | -0.50% | EXIT | |
| 34 | PLX | Protalix Biotherapeutics Inc | Stock-Other | 0.59% | -0.10% | EXIT | |
| 35 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.57% | -0.02% | -11.51% | |
| 36 | FBIO | Fortress Biotech Inc | Stock-Other | 0.53% | -0.13% | — | |
| 37 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.44% | -0.14% | — | |
| 38 | MGTX | MeiraGTx Holdings plc | Stock-Other | 0.41% | +1.92% | — | |
| 39 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 0.40% | -0.25% | EXIT | |
| 40 | ZYME | Zymeworks Inc | Stock-Other | 0.38% | — | +8.93% | |
| 41 | ✓ | Assertio Holdings Inc | Stock-Other | 0.34% | — | — | |
| 42 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.30% | — | — | |
| 43 | IRD | Opus Genetics Inc | Stock-Other | 0.30% | +0.12% | +1.82% | |
| 44 | STRO | Sutro Biopharma Inc | Stock-Other | 0.29% | -0.63% | EXIT | |
| 45 | CABA | Cabaletta Bio Inc | Stock-Other | 0.26% | +0.60% | +11.26% | |
| 46 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.25% | +0.18% | +342.55% | |
| 47 | ✓ | Stock-Other | 0.23% | — | — | ||
| 48 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.18% | — | — | |
| 49 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.16% | -0.04% | — | |
| 50 | QTTB | Q32 Bio Inc | Stock-Other | 0.09% | +0.01% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LQDA | Liquidia CORP | +2.8% | -6.88% | Trim |
| 2 | APGE | Apogee Therapeutics Inc | +1.8% | +6.88% | Add |
| 3 | ✓ | +1.7% | +121.51% | Add | |
| 4 | ACOG | Alpha Cognition Inc | +1.7% | +1698.46% | Add |
| 5 | RZLT | Rezolute Inc | +0.8% | +595.91% | Add |
| 6 | STOK | Stoke Therapeutics Inc | +0.6% | +1.90% | Add |
| 7 | ANNX | Annexon Inc | +0.6% | — | Unchanged |
| 8 | EWTX | Edgewise Therapeutics Inc | +0.5% | — | Unchanged |
| 9 | MBX | Mbx Biosciences Inc | +0.5% | +2.77% | Add |
| 10 | RVMD | Revolution Medicines Inc | +0.4% | — | Unchanged |
| 11 | ALMS | Alumis Inc | +0.3% | -19.55% | Trim |
| 12 | IRON | Disc Medicine Inc | +0.3% | +3.21% | Add |
| 13 | RIGL | Rigel Pharmaceuticals Inc | +0.3% | +85.25% | Add |
| 14 | PTGX | Protagonist Therapeutics Inc | +0.2% | — | Unchanged |
| 15 | ZNTL | Zentalis Pharmaceuticals Inc | +0.2% | +342.55% | Add |
| 16 | ZYME | Zymeworks Inc | +0.1% | +8.93% | Add |
| 17 | GOSS | Gossamer Bio Inc | +0.1% | -0.18% | Trim |
| 18 | TRVI | Trevi Therapeutics Inc | +0.1% | -11.51% | Trim |
| 19 | IRD | Opus Genetics Inc | 0% | +1.82% | Add |
| 20 | DERM | Journey Medical CORP | 0% | +0.41% | Add |
| 21 | CABA | Cabaletta Bio Inc | 0% | +11.26% | Add |
| 22 | ADGM | Adagio Medical Holdings Inc | 0% | -83.32% | Trim |
| 23 | CGON | Cg Oncology Inc | -0.1% | — | Unchanged |
| 24 | OCUL | Ocular Therapeutix Inc | -0.1% | — | Unchanged |
| 25 | ALKS | Alkermes plc | -0.1% | +8.89% | Add |
| 26 | PLX | Protalix Biotherapeutics Inc | -0.2% | -3.97% | Trim |
| 27 | XOMA | Xoma Royalty Corporation | -0.4% | +14.70% | Add |
| 28 | TGTX | Tg Therapeutics Inc | -0.6% | — | Unchanged |
| 29 | SNWV | Sanuwave Health Inc | -1.3% | +0.13% | Add |
| 30 | HROW | Harrow Inc | -1.4% | — | Unchanged |
| 31 | RYTM | Rhythm Pharmaceuticals Inc | -1.9% | -28.52% | Trim |
| 32 | ETON | Eton Pharmaceuticals Inc | -2.4% | — | Unchanged |
| 33 | CDXS | Codexis Inc | -3% | -46.93% | Trim |
| 34 | IMNM | Immunome Inc | — | EXIT | Sold out |
| 35 | ✓ | Crescent Biopharma Inc. | — | NEW | New buy |
| 36 | SRPT | Sarepta Therapeutics Inc | — | EXIT | Sold out |
| 37 | LRMR | Larimar Therapeutics Inc | — | EXIT | Sold out |
| 38 | ARVN | Arvinas Inc | — | EXIT | Sold out |
| 39 | KPTI | Karyopharm Therapeutics Inc | — | NEW | New buy |
| 40 | JBIO | Jade Biosciences Inc | — | NEW | New buy |
| 41 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
| 42 | CATX | Perspective Therapeutics Inc | — | NEW | New buy |
| 43 | TMCI | Treace Medical Concepts Inc | — | EXIT | Sold out |
| 44 | VYGR | Voyager Therapeutics Inc | — | NEW | New buy |
| 45 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | — | EXIT | Sold out |
| 46 | RLMD | Relmada Therapeutics Inc | — | NEW | New buy |
| 47 | TECX | Tectonic Therapeutic Inc | — | NEW | New buy |
| 48 | FBIO | Fortress Biotech Inc | — | NEW | New buy |
| 49 | RCKT | Rocket Pharmaceuticals Inc | — | NEW | New buy |
| 50 | MGTX | MeiraGTx Holdings plc | — | NEW | New buy |
According to official SEC Form 13F filings, Opaleye Management Inc. reported a total U.S. public equity portfolio value of $1.1B across 54 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HROW, LQDA, ETON) accounted for 35.3% of total reported equity market value during Q4 2025.
Top New Position Initiated
CRESCENT BIOPHARMA INC.
市值: $14.0M
Top Position Liquidated / Trimmed
IMNM
前期市值: $37.3M
During Q4 2025, Opaleye Management Inc.'s top holdings by market value included HROW (25.3%)、LQDA (11.2%)、ETON (6.4%). The largest single position, HROW, represented 25.3% of total portfolio value.
In Q4 2025, Opaleye Management Inc. made 55 total portfolio adjustments, initiating 21 new buys, adding to 16 positions, trimming 8 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.